These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 2516891

  • 41. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [Abstract] [Full Text] [Related]

  • 42. [An echocardiographic study of the left ventricular functional indices in pediatric patients on hemodialysis and in treatment with recombinant human erythropoietin (r-HuEPO)].
    Seracini D, Pollini I, Lavoratti GC, Pela I, Materassi M, Danti D, De Simone L, Favilli S, Manetti A.
    Pediatr Med Chir; 1994 Jun; 16(4):389-92. PubMed ID: 7816703
    [Abstract] [Full Text] [Related]

  • 43. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).
    Roger SD, Baker LR, Raine AE.
    Clin Nephrol; 1993 Feb; 39(2):103-10. PubMed ID: 8448912
    [Abstract] [Full Text] [Related]

  • 44. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients.
    Lebel M, Kingma I, Grose JH, Langlois S.
    Am J Hypertens; 1995 Jun; 8(6):545-51. PubMed ID: 7662237
    [Abstract] [Full Text] [Related]

  • 45. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
    Abraham PA, Opsahl JA, Rachael KM, Asinger R, Halstenson CE.
    Am J Nephrol; 1990 Jun; 10(2):128-36. PubMed ID: 2349956
    [Abstract] [Full Text] [Related]

  • 46. Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin.
    Vanrenterghem Y, Vanwalleghem J.
    Nephrol Dial Transplant; 1998 Jun; 13 Suppl 2():13-5. PubMed ID: 9566485
    [Abstract] [Full Text] [Related]

  • 47. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
    BMJ; 1990 Mar 03; 300(6724):573-8. PubMed ID: 2108751
    [Abstract] [Full Text] [Related]

  • 48. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure.
    Morris KP, Skinner JR, Hunter S, Coulthard MG.
    Arch Dis Child; 1993 May 03; 68(5):644-8. PubMed ID: 8323333
    [Abstract] [Full Text] [Related]

  • 49. Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis.
    Nordström D, Lindroth Y, Marsal L, Hafström I, Henrich C, Rantapää-Dahlqvist S, Engström-Laurent A, Fyhrquist F, Friman C.
    Rheumatol Int; 1997 May 03; 17(2):67-73. PubMed ID: 9266623
    [Abstract] [Full Text] [Related]

  • 50. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin.
    Bárány P, Pettersson E, Konarski-Svensson JK.
    Nephrol Dial Transplant; 1993 May 03; 8(5):426-32. PubMed ID: 8393547
    [Abstract] [Full Text] [Related]

  • 51. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin.
    McMahon LP, Dawborn JK.
    Am J Nephrol; 1992 May 03; 12(3):162-9. PubMed ID: 1415377
    [Abstract] [Full Text] [Related]

  • 52. Erythrocyte vitamins B1, B2 and B6 and erythropoietin.
    Mydlik M, Derzsiová K.
    Am J Nephrol; 1993 May 03; 13(6):464-6. PubMed ID: 8141181
    [Abstract] [Full Text] [Related]

  • 53. Efficacy of C.E.R.A. in Routine Clinical Practice for Correction of Anaemia and Maintenance of the Haemoglobin Levels in CKD Patients not on Dialysis.
    Promod PJ, Deshpande R, Mohanty NK, Kulkarni S, Shah HA, Ganju A, Kukreja A, Joshi S.
    J Assoc Physicians India; 2017 Mar 03; 65(3):52-57. PubMed ID: 28462544
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.
    Abraham PA, Opsahl JA, Keshaviah PR, Collins AJ, Whalen JJ, Asinger RW, McLain LA, Hanson G, Davis MG, Halstenson CE.
    Am J Kidney Dis; 1990 Nov 03; 16(5):438-46. PubMed ID: 2239934
    [Abstract] [Full Text] [Related]

  • 56. Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit.
    Soffritti S, Russo G, Cantelli S, Gilli G, Catizone L.
    BMC Nephrol; 2009 Oct 24; 10():33. PubMed ID: 19852833
    [Abstract] [Full Text] [Related]

  • 57. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis.
    Harris DC, Chapman JR, Stewart JH, Lawrence S, Roger SD.
    Aust N Z J Med; 1991 Oct 24; 21(5):693-700. PubMed ID: 1759917
    [Abstract] [Full Text] [Related]

  • 58. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May 24; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.